Atom Investors’s Epizyme, Inc EPZM Stock Holding History

Atom Investors’s Portfolio EPZM Stock Details EPZM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-122,517	Closed	-$1.97M	–	658
2020 Q2	$1.97M	Sell	122,517 -126,108	-51%	-$2.2M	0.13%	137
2020 Q1	$3.86M	Buy	248,625 +2,022	+0.8%	+$43.4K	0.34%	72
2019 Q4	$6.07M	Buy	246,603 +4,959	+2%	+$73.6K	0.5%	65
2019 Q3	$2.49M	Buy	241,644 +47,550	+24%	+$600K	0.17%	143
2019 Q2	$2.44M	Buy	+194,094	New	+$2.5M	0.16%	171

Other funds holding EPZM

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

RP Management New York $139M AUM 37.98% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return

Atom Investors's EPZM Position: Q3 2020 in Review

Atom Investors sold out of Epizyme, Inc (EPZM) in Q3 2020, closing a stake of 122,517 shares — an estimated $1.97M sold.

Atom Investors first reported a position in EPZM in Q2 2019 and held it in 5 quarters. The position peaked at $6.07M in Q4 2019. 151 funds tracked by Wall St. Rank hold EPZM as of Q3 2020.

Atom Investors reported no remaining Epizyme, Inc position as of Q3 2020 after selling out during the quarter.
Atom Investors sold 122,517 Epizyme, Inc shares in Q3 2020, an estimated $1.97M.
Atom Investors first reported a position in Epizyme, Inc in Q2 2019 and held it in 5 quarters.
Atom Investors's Epizyme, Inc position peaked at $6.07M in Q4 2019.
151 funds tracked by Wall St. Rank held Epizyme, Inc as of Q3 2020.

Based on Atom Investors's 13F filing for Q3 2020, filed 13 Nov 2020.